Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01024686 · ClinicalTrials.gov registry record · Phase 1
Phase 1/2a Trial of Pf GAP p52-/p36- Sporozoite Malaria Vaccine
A Phase 1 study, sponsored by Seattle Children's Hospital.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT01024686: Clinical Trial Phase 1 study, sponsored by Seattle Children's Hospital.
NCT01024686 is a Phase 1 study that was terminated before completion, run by Seattle Children's Hospital. The registered enrollment target is 6 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01024686, a Phase 1 study, was terminated before completion, sponsored by Seattle Children's Hospital.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this study is to assess safety and tolerability of escalating doses of a genetically attenuated parasite malaria vaccine (p52-/p36- GAP vaccine) in healthy malaria-naive adults. The study will also assess preliminary efficacy of p52-/p36- GAP vaccine following primary experimental challenge with P. falciparum sporozoites. Lastly, the study will assess immunogenicity of p52-/p36- GAP in malaria-naïve healthy adults and preliminary efficacy of p52-/p36- GAP vaccine following primary experimental re-challenge with P. falciparum sporozoites.
Interventions
- BIOLOGICAL p52-/p36- GAP Vaccine
- BIOLOGICAL p52-p36- GAP Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2010-03 |
| Est. Completion | 2011-06 |
| Phase | Phase 1 |
Why NCT01024686 stopped before completion
NCT01024686 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 2 interventions - of which p52-/p36- GAP Vaccine is the first listed.
NCT01024686 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01024686 about?
NCT01024686 is a clinical study titled "Phase 1/2a Trial of Pf GAP p52-/p36- Sporozoite Malaria Vaccine". The purpose of this study is to assess safety and tolerability of escalating doses of a genetically attenuated parasite malaria vaccine (p52-/p36- GAP vaccine) in healthy malaria-naive adults. The study will also assess preliminary efficacy of p52-/p36- GAP vaccine following primary experimental cha...
What is the current status of trial NCT01024686?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2010-03. Estimated completion is 2011-06.
What interventions are being tested in trial NCT01024686?
The interventions under investigation include: p52-/p36- GAP Vaccine (BIOLOGICAL), p52-p36- GAP Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT01024686?
This trial is sponsored by Seattle Children's Hospital, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01024686's enrollment target sits among peer trials
6 1974th of 2000 higher than 12 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia